About Accretion Pharmaceuticals
Accretion Pharmaceuticals is a publicly listed company based in Ahmedabad (India) founded in 2012 by Harshad Rathod and Mayur Sojitra. Tablets, capsules, and oral liquids are manufactured for therapeutic categories. The company has 1 employees. Its Indian entity Accretion Pharmaceuticals Limited reported revenue of ₹89.82 Cr. Accretion Pharmaceuticals offers products and services including Pharmaceutical Products, Nutraceuticals, and Ayurveda Products. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Formulation. Similar companies include Akums, Jubilant Life Sciences and Nectar Lifesciences; 2 of its 3 listed similar companies have raised funding.
Company details
Accretion Pharmaceuticals was established in 2012 in Ahmedabad, India. Tablets, capsules, and oral liquids are produced across various therapeutic categories, including analgesics, antibiotics, antidiabetics, cardiovascular drugs, gastrointestinal treatments, vitamins, and minerals. Operations focus on pharmaceutical manufacturing within the healthcare sector, with distribution centered in India. Leadership includes co-founders Harshad Rathod and Mayur Sojitra.
- Headquarters Ahmedabad, India
- Employees 1
- Founders Harshad Rathod, Mayur Sojitra
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website accretionpharma.com
- Social LinkedIn Facebook
- Legal Name Accretion Pharmaceuticals Ltd.
- Market Cap₹201 Cr
ACCPL-ST · NSE
- Share Price₹190.05
+5.00% today
- Revenue₹89.63 Cr
FY 2025-26 · +56.2% YoY
- EBITDA₹14.95 Cr
Margin 16.7%
- Net Profit₹9.66 Cr
FY 2025-26 · +42.3% YoY
- P/E (TTM)21.3x
P/B 3.8x
- Employee Count1
Associated legal entities of Accretion Pharmaceuticals
Accretion Pharmaceuticals is associated with 2 registered companies on The Company Check; the primary company is Accretion Pharmaceuticals Limited, a listed company. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Accretion Pharmaceuticals Limited Listed CIN L21004GJ2023PLC146545 | Active | 29 Nov 2023 | Sanand, Gujarat | ₹89.8 Cr | 9 | View details | |
| Accretion Nutraveda Limited Listed CIN U24290GJ2021PLC121216 | Active | 16 Mar 2021 | Ahmedabad, Gujarat | ₹33.7 Cr | 11 | View details |
Products & Services of Accretion Pharmaceuticals
Accretion Pharmaceuticals offers a comprehensive portfolio of products and services, including Pharmaceutical Products, Nutraceuticals, and Ayurveda Products.
High-quality drugs and formulations for medical use
Nutritional products supporting wellness and health
Herbal formulations based on Ayurveda for natural health
Board of directors of Accretion Pharmaceuticals Limited (Accretion Pharmaceuticals)
Accretion Pharmaceuticals Limited is the primary company behind Accretion Pharmaceuticals. The boards of the 2 registered companies of Accretion Pharmaceuticals currently have 12 directors; the longest-serving is Hardik Mukundbhai Prajapati, appointed in 2021. 13 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Hardik Mukundbhai Prajapati DIN 09108403 | Director | 16 Mar 2021 | 5 yrs 7 mo | Accretion Nutraveda Limited, Accretion Pharmaceuticals Limited |
| Harshad Nanubhai Rathod DIN 09108392 | Director | 16 Mar 2021 | 5 yrs 7 mo | Accretion Nutraveda Limited, Accretion Pharmaceuticals Limited |
| Mayur Popatlal Sojitra DIN 09108404 | Managing Director | 16 Mar 2021 | 5 yrs 7 mo | Accretion Nutraveda Limited, Accretion Pharmaceuticals Limited |
| Vivek Ashok Kumar Patel DIN 09130357 | Director | 31 Mar 2021 | 5 yrs 7 mo | Accretion Nutraveda Limited, Accretion Pharmaceuticals Limited |
| Ankurkumar Shantilal Patel DIN 09130391 | Whole-time director | 31 Mar 2021 | 5 yrs 7 mo | Accretion Nutraveda Limited |
| Grishma A Shewale DIN 10685826 | Director | 09 Jul 2024 | 2 yrs 3 mo | Accretion Pharmaceuticals Limited |
| Chand Rameshbhai Kanabar DIN 10706050 | Director | 19 Apr 2025 | 1 yr 6 mo | Accretion Pharmaceuticals Limited |
| Nishtha Harivanshi Pamnani DIN 10881910 | Director | 10 Jun 2025 | 1 yr 4 mo | Accretion Pharmaceuticals Limited |
| Shruti Gupta DIN 10310259 | Director | 11 Sep 2025 | 1 yr 1 mo | Accretion Nutraveda Limited |
| Mahipal Singh Chouhan DIN 08977710 | Director | 11 Sep 2025 | 1 yr 1 mo | Accretion Nutraveda Limited |
| Arun Dash DIN 09657537 | Director | 11 Sep 2025 | 1 yr 1 mo | Accretion Nutraveda Limited |
| Paraskumar Vinubhai Parmar DIN 10952040 | CFO | 11 Sep 2025 | 1 yr 1 mo | Accretion Nutraveda Limited |
People of Accretion Pharmaceuticals
2 people are tracked at Accretion Pharmaceuticals (2 in leadership); the tracked headcount is 1.
| Name | Role | Group |
|---|---|---|
| Co-Founder | Leadership | |
| Co-Founder | Leadership |
Complete people profiles for Accretion Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Accretion Pharmaceuticals
Accretion Pharmaceuticals is a publicly listed company on the NSE with ticker symbol ACCPL in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date21 May 2025
- Listed onNSE: ACCPL
- Listed entityAccretion Pharmaceuticals Ltd.
- Exchange sectorHealth technology
- ISININE0T8T01010
- Share price₹193.20 (+1.68% on the day) · 2026-10-13
- Market capitalisation₹215 Cr
- Price to earnings22.2
- EPS (diluted, trailing year)₹8.70
- Volume (last session)4,800
Financials of Accretion Pharmaceuticals
Exchange-reported figures of Accretion Pharmaceuticals Limited, the listed company behind Accretion Pharmaceuticals (NSE: ACCPL-ST).
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Income statement | |||
| Revenue | 89.63 | 57.38 | 13.35 |
| Revenue growth | +56.2% | +329.8% | - |
| EBITDA | 14.95 | 11.88 | 2.56 |
| EBITDA margin | +16.7% | +20.7% | +19.2% |
| Profit before tax | 13.08 | 9.76 | 1.99 |
| Net profit | 9.66 | 6.79 | 1.49 |
| Net profit margin | +10.8% | +11.8% | +11.2% |
| EPS (₹) | 9.03 | 8.32 | 3.73 |
| Balance sheet | |||
| Total assets | 67.03 | 29.39 | 18.97 |
| Net worth | 54.71 | 15.29 | 5.49 |
| Total debt | 12.32 | 14.10 | 13.48 |
| Cash & bank | 4.02 | 0.05 | 0.09 |
| Net working capital | 51.01 | 23.14 | 13.58 |
| Cash flow | |||
| Cash from operations | (14.53) | (0.62) | (11.51) |
| Cash from investing | (8.53) | (1.61) | (5.48) |
| Cash from financing | 27.04 | 2.19 | 17.08 |
Financial Statements
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Revenue | 89.63 | 57.38 | 13.35 |
| Revenue growth | +56.2% | +329.8% | - |
| Other income | 0.19 | 0.09 | 0.05 |
| Total expenses | 74.68 | 45.50 | 10.79 |
| Employee cost | 0.00 | 3.04 | 0.79 |
| EBITDA | 14.95 | 11.88 | 2.56 |
| EBITDA margin | +16.7% | +20.7% | +19.2% |
| Depreciation | 1.21 | 0.77 | 0.22 |
| Interest | 0.85 | 1.44 | 0.40 |
| Profit before tax | 13.08 | 9.76 | 1.99 |
| Tax | 3.42 | 2.97 | 0.50 |
| Net profit | 9.66 | 6.79 | 1.49 |
| Net profit margin | +10.8% | +11.8% | +11.2% |
| EPS (₹) | 9.03 | 8.32 | 3.73 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Equity & liabilities | |||
| Share capital | 11.12 | 8.17 | 4.00 |
| Reserves & surplus | 43.59 | 7.12 | 1.49 |
| Shareholders' funds (net worth) | 54.71 | 15.29 | 5.49 |
| Secured loans | 8.98 | 9.62 | 5.24 |
| Unsecured loans | 3.34 | 4.48 | 8.24 |
| Total debt | 12.32 | 14.10 | 13.48 |
| Total liabilities | 67.03 | 29.39 | 18.97 |
| Assets | |||
| Gross block | 15.42 | 7.09 | 5.48 |
| Net block | 13.21 | 6.09 | 5.26 |
| Capital work in progress | 0.20 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 |
| Inventories | 28.37 | 20.61 | 14.48 |
| Sundry debtors | 22.40 | 11.66 | 5.80 |
| Cash & bank balances | 4.02 | 0.05 | 0.09 |
| Loans & advances | 5.60 | 1.12 | 1.68 |
| Total current assets | 60.39 | 33.44 | 22.05 |
| Total current liabilities | 9.38 | 10.30 | 8.47 |
| Net working capital | 51.01 | 23.14 | 13.58 |
| Total assets | 67.03 | 29.39 | 18.97 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Opening cash | 0.05 | 0.09 | 0.00 |
| Net cash from operating activities | (14.53) | (0.62) | (11.51) |
| Net cash from investing activities | (8.53) | (1.61) | (5.48) |
| Net cash from financing activities | 27.04 | 2.19 | 17.08 |
| Net change in cash | 3.97 | (0.04) | 0.09 |
| Closing cash | 4.02 | 0.05 | 0.09 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Growth | |||
| Sales growth | +56.2% | +329.8% | - |
| EBITDA growth | +25.8% | +364.1% | - |
| PBT growth | +34.0% | +390.5% | +9997.0% |
| Net income growth | +42.3% | +355.7% | - |
| Profitability & leverage | |||
| Net income margin | +10.8% | +11.8% | +11.2% |
| Return on capital employed | - | +46.3% | +12.6% |
| Return on net worth | - | +65.4% | +27.1% |
| Debt / equity | - | 1.33 | 2.46 |
| Long-term debt / equity | - | 0.39 | 1.26 |
| Interest cover | 6.19 | 12.96 | 17.09 |
| Efficiency & per share | |||
| Fixed asset turnover | - | 9.13 | 2.44 |
| Inventory turnover | - | 3.27 | 0.92 |
| Debtors turnover | - | 6.57 | 2.30 |
| EPS (₹) | 9.03 | 8.32 | 3.73 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 18.71 | 13.73 |
Similar companies to Accretion Pharmaceuticals
Accretion Pharmaceuticals has 3 listed similar companies in our database, 2 of them funded. They include Akums, Jubilant Life Sciences and Nectar Lifesciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| akums.in | 2004 | Delhi, India | $70M | 395 | CDMO focusing on spectrum of dosage forms and therapeutic segments | |
| jubl.com | 1978 | Noida, India | Company offering a suite of R&D and manufacturing services for small molecules and generics | |||
| neclife.com | 1995 | Chandigarh, India | $46.85M | 175 | Cephalosporin APIs and generic formulations are manufactured. |
Detailed similar companies of Accretion Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Accretion Pharmaceuticals
The website of Accretion Pharmaceuticals (accretionpharma.com) receives about 1.8K visits a month.
- Monthly visits1.8K
▲ 53.8% vs previous month
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Accretion Pharmaceuticals (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Accretion Pharmaceuticals
Complete news archive for Accretion Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Accretion Pharmaceuticals
Accretion Pharmaceuticals was founded in 2012.
Accretion Pharmaceuticals is headquartered in Ahmedabad, India. It is registered at Ahmedabad, Gujarat, India.
Accretion Pharmaceuticals has 1 employees.
The primary company behind Accretion Pharmaceuticals, Accretion Pharmaceuticals Limited, reported revenue of ₹89.82 Cr for FY 2026, up 56% year on year.
Accretion Pharmaceuticals was established in 2012 in Ahmedabad, India. Tablets, capsules, and oral liquids are produced across various therapeutic categories, including analgesics, antibiotics, antidiabetics, cardiovascular drugs, gastrointestinal treatments, vitamins, and minerals. Operations focus on pharmaceutical manufacturing within the healthcare sector, with distribution centered in India. Leadership includes co-founders Harshad Rathod and Mayur Sojitra.
Accretion Pharmaceuticals's top competitors include Jubilant Life Sciences, Akums and Nectar Lifesciences.
Accretion Pharmaceuticals offers Pharmaceutical Products, Nutraceuticals, and Ayurveda Products.
Yes, Accretion Pharmaceuticals is publicly traded on NSE under the ticker symbol ACCPL.
Accretion Pharmaceuticals is associated with 2 legal entities: Accretion Pharmaceuticals Limited, Accretion Nutraveda Limited.
The legal entities of Accretion Pharmaceuticals currently have 14 directors, including Hardik Mukundbhai Prajapati, Harshad Nanubhai Rathod, Mayur Popatlal Sojitra and others.